Compare CSTL & AMBQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTL | AMBQ |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.7M | 533.3M |
| IPO Year | 2019 | 2025 |
| Metric | CSTL | AMBQ |
|---|---|---|
| Price | $39.29 | $29.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $42.83 | $41.75 |
| AVG Volume (30 Days) | ★ 370.2K | 85.9K |
| Earning Date | 11-03-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $343,530,000.00 | $72,109,000.00 |
| Revenue This Year | $1.69 | N/A |
| Revenue Next Year | N/A | $22.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.15 | 10.03 |
| 52 Week Low | $14.59 | $22.12 |
| 52 Week High | $42.18 | $51.76 |
| Indicator | CSTL | AMBQ |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | N/A |
| Support Level | $37.76 | N/A |
| Resistance Level | $42.18 | N/A |
| Average True Range (ATR) | 1.20 | 0.00 |
| MACD | -0.35 | 0.00 |
| Stochastic Oscillator | 46.17 | 0.00 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.